Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer’s Disease
Simufilam is a novel oral drug candidate in Phase 3 clinical trials for Alzheimer’s disease (AD) dementia. This small molecule binds an altered form of filamin A (FLNA) that occurs in AD. This drug action disrupts FLNA’s aberrant linkage to the α7 nicotinic acetylcholine receptor (α7nAChR), thereby...
Main Authors: | Hoau-Yan Wang, Erika Cecon, Julie Dam, Zhe Pei, Ralf Jockers, Lindsay H. Burns |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/18/13927 |
Similar Items
-
Inflammatory signaling of HMGB1 in depressive disorder
by: Qian Jiang, et al.
Published: (2023-11-01) -
Post-Translational Modification of HMGB1 Disulfide Bonds in Stimulating and Inhibiting Inflammation
by: Ulf Andersson, et al.
Published: (2021-11-01) -
Glycyrrhizin Interacts with TLR4 and TLR9 to Resolve <i>P. aeruginosa</i> Keratitis
by: Mallika Somayajulu, et al.
Published: (2022-11-01) -
Paroxetine effect on expression of TLR2 and TLR4 genes in PBMCs of mentally normal individuals
by: Fatemeh Ganjalishahi, et al.
Published: (2021-08-01) -
Toll-Like Receptor 4 and Inflammatory Micro-Environment of Pancreatic Islets in Type-2 Diabetes Mellitus: A Therapeutic Perspective
by: Wang Z, et al.
Published: (2020-11-01)